Newsgroup: it.salute
Titolo: Interessanti scoperte su statine e sclerosi multipla

Pare che nei topi le statine (i farmaci contro le ipercolesterolemie)
svolgano una azione benefica nei confronti della sclerosi multipla.
http://www.cnn.com/2002/HEALTH/conditions/11/06/ms.treatment.ap/index.html
Speriamo che le premesse trovino conferme per giungere ad una
applicazione pratica dopo una debita sperimentazione sull'uomo.
-- 
Ignazio GSS© * More than 90 HiRes images in my home page  
http://www.geocities.com/ipuddu/
200 Images of digestive endoscopy
http://www.areamedica.com


http://www.cnn.com/2002/HEALTH/conditions/11/06/ms.treatment.ap/index.html
Darò un'occhiata a questo indirizzo. Grazie! Già su Nature del 7 nov. hanno
pubblicato una nuova ricerca che dimostrava un forte effetto preventivo e
terapeutico di una statina (atorvastatina) su topi affetti da EAE (modello
sperimentale della SM).  Negli Stati Uniti è in corso un piccolo studio
clinico con la simvastatina mentre, tra pochi mesi dovrebbe iniziare uno
studio più grande con l'atorvastatina.
Purtroppo gli umani non hanno la coda e, non sempre ciò che funziona nei topi
con EAE da i medesimi risultati positivi negli umani affetti da SM (la EAE è
solo un modello sperimentale).
Cmq sia, staremo a vedere! (W i topi!)
Grazie Ignazio! Bye, Alessio

pare che abbiano anche azione antitumorale..
http://www.medicine.mcgill.ca/pharma/statin%20and%20apoptosis.pdf
carlitos.

Ciao Ignazio, salve a tutti
Copio ed incollo un brano apparso nel maggio scorso su Medscape (atti del 54°
meeting annuale della AAN American Academy of Neurology).
Buon weekend, Alessio
*/*
Statins
One of the most intriguing possible future therapies for MS is the use of
statin agents. Animal work by Scott Zamvil and colleagues[14] from the
University of California, San Francisco, and in vitro human work from a German
and Austrian group[15] demonstrated the possible mechanism of action of
statins in animal models of disease (EAE) and in manipulating lymphocytes and
cytokines. Atorvastatin, initiated at the onset of induction of chronic EAE,
reversed paralysis and could ameliorate relapses in a relapsing EAE model. Dr.
Zamvil's elegant work histologically examined the brains and spinal cords of
treated animals, finding significant reductions in both the number of
perivascular lesions and the extent of infiltration. He also showed that
lymphocytes from atorvastatin-treated mice demonstrated decreased IFN-beta and
increased interleukin (IL)-4 and IL-10 secretion, thus promoting a Th2 bias,
thought to be protective of disease.
In vitro, various statins were added to lymphocytes obtained from untreated MS
patients or those treated with IFN-beta-1b, and statin effects were seen on
all cells regardless of their source: reduced expression of lymphocyte
activation markers; increased production of IL-4 (ie, driving a protective
Th2-type immunologic response); and downregulated expression of chemokine
receptors on both B and T cells. In some cases, particularly the inhibitory
effects of IFN-beta-1b, statins were additive, suggesting that they may be
used either singly or as add-on therapy for MS.
[14] Youssef S, Stuve O, Ruiz PJ, Steinman L, Zamvil Stanford SS.
Atorvastatin, HMG-CoA reductase inhibitor, promotes a Th2 bias and reversal of
paralysis in chronic relapsing autoimmune encephalomyelitis. Program and
abstracts of the 54th Annual Meeting of the American Academy of Neurology;
April 13-20, 2002; Denver, Colorado. Abstract P05.119.
[15] Neuhaus O, Strasser-Fuchs S, Fazekas F, Hartung H-P, Archelos Graz JJ.
Multiple sclerosis: immunological effects of statins in vitro -- a new
therapeutical approach? Program and abstracts of the 54th Annual Meeting of
the American Academy of Neurology; April 13-20, 2002; Denver, Colorado.
Abstract P01.141.